Rankings
▼
Calendar
AXSM (Axsome Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena
AXSM
Axsome Therapeutics, Inc.
Mkt Cap
$9B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$638M
Net Income (TTM)
-$183M
EPS (TTM)
-$3.69
Free Cash Flow (TTM)
-$94M
Gross Margin
92.6%
Op. Margin
-26.5%
Net Margin
-28.7%
FCF Margin
-14.7%
P/S Ratio (TTM)
13.4x
P/E Ratio (TTM)
—
YoY Rev Growth
+65.5%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$95M
$87M
-$6M
Q2 23
$47M
$42M
-$65M
Q3 23
$58M
$51M
-$62M
Q4 23
$72M
$64M
-$98M
Q1 24
$75M
$69M
-$67M
Q2 24
$87M
$79M
-$78M
Q3 24
$105M
$96M
-$63M
Q4 24
$119M
$108M
-$73M
Q1 25
$121M
$112M
-$57M
Q2 25
$150M
$137M
-$37M
Q3 25
$171M
$159M
-$46M
Q4 25
$196M
$184M
-$29M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
59.3x
—
Q2 23
47.0x
—
Q3 23
38.4x
—
Q4 23
31.7x
—
Q1 24
34.2x
—
Q2 24
29.4x
—
Q3 24
25.3x
—
Q4 24
22.2x
—
Q1 25
19.9x
—
Q2 25
17.3x
—
Q3 25
15.3x
—
Q4 25
13.4x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$6M
-$6M
Q2 23
-$55M
-$55M
Q3 23
-$54M
-$54M
Q4 23
-$30M
-$30M
Q1 24
-$53M
-$54M
Q2 24
-$30M
-$30M
Q3 24
-$19M
-$18M
Q4 24
-$26M
-$26M
Q1 25
-$43M
-$43M
Q2 25
-$32M
-$32M
Q3 25
$1M
$988K
Q4 25
-$19M
-$19M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$71K
Q2 23
$133K
Q3 23
$371K
Q4 23
$7K
Q1 24
$98K
Q2 24
$52K
Q3 24
$150K
Q4 24
$30K
Q1 25
$0
Q2 25
$0
Q3 25
$58K
Q4 25
$351K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
—
+163.7%
Q2 23
+429.5%
+132.8%
Q3 23
+243.1%
+102.4%
Q4 23
+193.5%
+101.5%
Q1 24
-20.7%
+40.9%
Q2 24
+86.7%
+47.8%
Q3 24
+81.3%
+39.6%
Q4 24
+66.0%
+12.7%
Q1 25
+62.0%
+25.4%
Q2 25
+72.1%
+13.0%
Q3 25
+63.2%
+29.7%
Q4 25
+65.0%
+17.8%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$13M
13.7%
Q2 23
$16M
34.1%
Q3 23
$15M
25.7%
Q4 23
$19M
26.4%
Q1 24
$20M
26.9%
Q2 24
$21M
24.5%
Q3 24
$22M
20.7%
Q4 24
$22M
18.5%
Q1 25
$23M
19.2%
Q2 25
$25M
16.4%
Q3 25
$23M
13.5%
Q4 25
$0
0.0%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$18M
—
—
$74M
Q2 23
$21M
$52M
$27M
—
Q3 23
$29M
—
—
$83M
Q4 23
$31M
—
—
$87M
Q1 24
$37M
—
—
$99M
Q2 24
$50M
—
—
$104M
Q3 24
$45M
—
—
$96M
Q4 24
$55M
—
—
$113M
Q1 25
$45M
—
—
$121M
Q2 25
$50M
$94M
$36M
—
Q3 25
$40M
$109M
$41M
—
Q4 25
$49M
—
—
$169M
marketcaparena.com
Revenue Segments
License
Product
Royalty
Quarter
License
Product
Royalty
Q1 23
$66M
$29M
$272K
Q2 23
—
$46M
$683K
Q4 23
—
$71M
$783K
Q1 24
—
$74M
$903K
Q2 24
—
$87M
$646K
Q3 24
—
$104M
$1M
Q1 25
—
$120M
$1M
Q2 25
—
$149M
$1M
Q3 25
—
$170M
$2M
Q4 25
—
$195M
—
marketcaparena.com
Revenue by Geography
Non-US
United States
Quarter
Non-US
United States
Q3 23
$1M
$56M
Q1 24
$903K
$73M
Q2 24
$1M
$85M
Q3 24
$1M
$103M
Q4 24
$1M
$117M
Q1 25
$1M
$119M
Q2 25
$3M
$146M
Q3 25
$1M
$169M
Q4 25
$353K
$194M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$247M
$0
$247M
Q2 23
$437M
$0
$437M
Q3 23
$417M
$0
$417M
Q4 23
$386M
$0
$386M
Q1 24
$331M
$0
$331M
Q2 24
$316M
$0
$316M
Q3 24
$327M
$0
$327M
Q4 24
$315M
$0
$315M
Q1 25
$301M
$0
$301M
Q2 25
$303M
$0
$303M
Q3 25
$325M
$0
$325M
Q4 25
$323M
$0
$323M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
44M
+0.2%
Q2 23
44M
+0.3%
Q3 23
47M
+7.9%
Q4 23
47M
+0.5%
Q1 24
47M
+0.1%
Q2 24
48M
+0.4%
Q3 24
48M
+1.2%
Q4 24
49M
+0.8%
Q1 25
49M
+0.7%
Q2 25
49M
+1.2%
Q3 25
50M
+1.2%
Q4 25
51M
+1.2%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
$0
11
FY 16
$0
22
FY 17
$0
25
FY 18
$0
29
FY 19
$0
45
FY 20
$0
60
FY 21
$0
108
FY 22
$131K
383
FY 23
$497K
545
FY 24
$565K
683
FY 25
$690K
925
marketcaparena.com